At a glance
- Originator Chiesi
- Class Antiplatelets; Vasodilators
- Mechanism of Action Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Thrombosis
Most Recent Events
- 20 May 1998 Discontinued-Preclinical for Atherosclerosis in Italy (Unknown route)
- 20 May 1998 Discontinued-Preclinical for Thrombosis in Italy (Unknown route)
- 14 Oct 1996 New profile